03.30.26 -- The Long Road To U.S. Vaccine Manufacturing

Adenoviruses are being reimagined as powerful tools for oncolytic cancer therapy, using their immunogenicity, tumor selectivity, and synergy with immunotherapy to drive new clinical progress.

Stepwise engineering produces ABEs with tunable potency, precision, PAM range, and context specificity, enabling robust and targeted genome editing across diverse therapeutic sites.

Discover how this cell separation system outperformed standard magnetic methods in T cell recovery, speed, and scalability, achieving higher cell quality with an innovative microbubble technology.

Expedited cell therapy pathways demand early, reliable analytical development to ensure robust data, regulatory confidence, and smooth transitions from discovery through clinical stages without costly delays.

An institute researching CRISPR-based genome editing required a custom, highly pure, ultra-low endotoxin nuclease. See how this expert partnership developed a transient Cas9 RNP.

Economic volatility, regulatory uncertainty, and capacity constraints pose major risks to CDMOs, threatening growth, profitability, and long-term sustainability in an increasingly competitive global market.

Early functional screening accelerates therapeutic antibody discovery, improving hit rates and efficiency through advanced platforms like hybridoma upgrades, single B cell workflows, and tailored phage display strategies.

Explore how the following framework can accelerate your viral vector, CAR-T, and iPSC programs, reduce risk, and streamline your path from development to commercial manufacturing.

Compare various strategies for generating both clonal and pooled protein expression lines; inducible expression can be efficiently achieved within just 4-6 weeks after donor plasmid creation.